Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

(2014) Timothy Iveson et al.   LANCET ONCOLOGY

Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients

(2013) Min Zhu et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Simulations Using a Drug–Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non–Small-Cell Lung Cancer

(2012) L Claret et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

MET Expression and Amplification in Patients with Localized Gastric Cancer

(2011) Y. Y. Janjigian et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer

(2010) Laurent Claret et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

(2010) M. S. Gordon et al.   CLINICAL CANCER RESEARCH

The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment

(2010) P. Accornero et al.   CURRENT MEDICINAL CHEMISTRY

Model-Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development

(2010) Jeffrey D. Wetherington et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Modeling and Simulation Framework to Support Early Clinical Drug Development Decisions in Oncology

(2010) Rene Bruno et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

(2009) C.-F. Gao et al.   MOLECULAR CANCER THERAPEUTICS

Recommended changes to oncology clinical trial design: Revolution or evolution?

(2007) Mark J. Ratain et al.   EUROPEAN JOURNAL OF CANCER